Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS
FDA Law Blog
NOVEMBER 6, 2022
In its petition filed earlier this month, Pfizer challenges HHS’s interpretation of the AKS as “staggeringly overbroad,” contrary to the congressional intent behind the AKS, and a threat to “almost any activity that facilitates patient access to federally funded healthcare.” Borrasi, 639 F.3d 3d 774 (7th Cir. Pfizer’s Petition to SCOTUS.
83 
Let's personalize your content